Frontier Capital Management’s Amedisys AMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-373,731
Closed -$36.2M 263
2022
Q3
$36.2M Sell
373,731
-19,746
-5% -$2.35M 0.42% 82
2022
Q2
$41.4M Buy
393,477
+52,736
+15% +$6.74M 0.48% 71
2022
Q1
$58.7M Buy
340,741
+168,949
+98% +$25.2M 0.53% 63
2021
Q4
$27.8M Sell
171,792
-20,595
-11% -$3.31M 0.22% 147
2021
Q3
$28.7M Sell
192,387
-15,496
-7% -$3.22M 0.23% 142
2021
Q2
$50.9M Sell
207,883
-24,481
-11% -$6.42M 0.37% 101
2021
Q1
$61.5M Buy
+232,364
New +$65.5M 0.47% 73

Other funds holding AMED

Frontier Capital Management's AMED Position: Q4 2022 in Review

Frontier Capital Management sold out of Amedisys (AMED) in Q4 2022, closing a stake of 373,731 shares — an estimated $36.2M sold.

Frontier Capital Management first reported a position in AMED in Q1 2021 and held it in 7 quarters. The position peaked at $61.5M in Q1 2021. 278 funds tracked by Wall St. Rank hold AMED as of Q4 2022.

  • Frontier Capital Management reported no remaining Amedisys position as of Q4 2022 after selling out during the quarter.
  • Frontier Capital Management sold 373,731 Amedisys shares in Q4 2022, an estimated $36.2M.
  • Frontier Capital Management first reported a position in Amedisys in Q1 2021 and held it in 7 quarters.
  • Frontier Capital Management's Amedisys position peaked at $61.5M in Q1 2021.
  • 278 funds tracked by Wall St. Rank held Amedisys as of Q4 2022.

Based on Frontier Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.